In non-small cell lung cancer (NSCLC), patients who relapsed with MET-amplified epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-resistant disease following treatment with an EGFR inhibitor harbored a low-frequency subclone (<1% of cells) with MET amplification prior to treatment, which was selected for during therapy [41]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.